{"slug":"thymalin","seoKey":"thymalin","displayName":"Thymalin","codes":[],"synonyms":["Тималин","Timalin","thymalinum","тимуса экстракт","thymus polypeptide complex","calf thymus polypeptide extract"],"legalClass":"rx","identifiers":{},"approvals":[{"market":"US","status":"not_approved","note":"Not approved, and expressly objected to. Four independent queries on 2026-09-17, of the approval database, the national drug code directory, the labelling archive and the recall database, all returned no match, while a control query returned one. The substance appears on none of the lists of bulk substances usable in pharmacy compounding. In February 2024 the regulator issued a warning letter to a vendor offering it for sale, naming it as an unapproved and misbranded new drug and separately criticising that it was marketed for use in children; a 'research chemicals only, not for human consumption' label on the product did not change that assessment.","source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-chem-labs-669074-02072024"},{"market":"EU","status":"not_approved","note":"Not approved. There is no centralised authorisation, no withdrawn application, no assessment report and no orphan designation: full-text searches of the official medicines dataset and of the orphan designations dataset on 2026-09-17 returned no match for any spelling of the name, against control substances that were found in the same files. As a medicine derived from bovine tissue it would additionally have to satisfy the requirements for starting materials of animal origin.","source":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx"},{"market":"DE","status":"not_approved","note":"Not approved and not marketable. With neither a European nor a national authorisation, placing it on the market falls under the authorisation requirement of the medicines act. It is not named in the prescription-only annex, which changes nothing: that annex governs the prescription status of authorised substances only. It is likewise absent from the annex to the anti-doping act, whose sole thymosin entry concerns thymosin beta-4.","source":"https://www.gesetze-im-internet.de/amvv/anlage_1.html"},{"market":"UK","status":"not_approved","note":"No authorisation identified. IMPORTANT CAVEAT: this is not a primary-verified negative finding. The regulator's product search returned HTTP 200 on 2026-09-17 but renders its result list only through client-side scripting, and the underlying search interface answered with HTTP 403, so no result could be read from the working environment. Supply would at most be conceivable as an unlicensed medicine against a named-patient prescription.","source":"https://products.mhra.gov.uk/search/?search=thymalin"},{"market":"AU","status":"not_approved","note":"Not scheduled, and no registration identified. The full text of the Poisons Standard of June 2026 was searched on 2026-09-17 with no match for the name or for thymus preparations, while control substances returned several matches each, so the search was working. CAVEAT: the register of therapeutic goods was unreachable across repeated attempts, including with a control term, so a registration could be neither confirmed nor excluded. An unregistered therapeutic good may not be supplied there in any case.","source":"https://www.legislation.gov.au/F2026L00633"},{"market":"CA","status":"not_approved","note":"Not approved. The active-ingredient query of the drug product database returned an empty list on 2026-09-17. A broader query on the tissue name returned only three homeopathic or natural health product entries and no injectable preparation, while a control query returned two matches with strengths.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=thymalin"},{"market":"CH","status":"not_approved","note":"Not approved. Two published lists of authorised human medicines were downloaded and searched in full on 2026-09-17 with no match for any spelling. Two near matches in those files belong elsewhere: one is an anti-thymocyte globulin product, the other is an extract of the culinary herb thyme. Control substances were found in both files.","source":"https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html"}],"devStage":"approved","strongestEvidence":"observational","wada":{"status":"not_listed","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":[],"lastVerified":"2026-09-17","version":"1.0","published":true,"locale":"en","title":"Thymalin: what the studies show, status and safety","summary":"Thymalin is not a single molecule but a mixture of peptides extracted from the thymus glands of calves. It is approved and prescription-only in Russia, and in no other market checked for this page. It has no defined structure, and therefore no formula, no registry number and no database entry of its own. The identifier circulating under its name in peptide lists belongs to a different substance. The claims made for it rest on a small, unregistered body of work, published mostly in Russian before 2000 by the group that developed it.","updated":"2026-09-17","url":"https://mypep.app/peptides/thymalin"}